Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BSX 
Boston Scientific Corp (BSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: BSX (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
34 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $117.55
1 Year Target Price $117.55
| 23 | Strong Buy |
| 8 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 58.22% | Avg. Invested days 71 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 154.34B USD | Price to earnings Ratio 76.15 | 1Y Target Price 117.55 |
Price to earnings Ratio 76.15 | 1Y Target Price 117.55 | ||
Volume (30-day avg) 34 | Beta 0.69 | 52 Weeks Range 71.88 - 107.53 | Updated Date 07/4/2025 |
52 Weeks Range 71.88 - 107.53 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.58% | Operating Margin (TTM) 20.09% |
Management Effectiveness
Return on Assets (TTM) 5.28% | Return on Equity (TTM) 9.5% |
Valuation
Trailing PE 76.15 | Forward PE 35.59 | Enterprise Value 164298024732 | Price to Sales(TTM) 8.79 |
Enterprise Value 164298024732 | Price to Sales(TTM) 8.79 | ||
Enterprise Value to Revenue 9.36 | Enterprise Value to EBITDA 40.2 | Shares Outstanding 1479449984 | Shares Floating 1475274306 |
Shares Outstanding 1479449984 | Shares Floating 1475274306 | ||
Percent Insiders 0.18 | Percent Institutions 93.22 |
Upturn AI SWOT
Boston Scientific Corp
Company Overview
History and Background
Boston Scientific was founded in 1979. It has grown through innovation and acquisitions, focusing on less-invasive medical technologies.
Core Business Areas
- MedSurg: This segment includes products used in endoscopy, urology and pelvic health, and peripheral interventions. It offers diagnostic and therapeutic devices to treat a range of medical conditions through minimally invasive procedures.
- Cardiology: This segment focuses on interventional cardiology, electrophysiology, and structural heart products. It includes devices such as stents, pacemakers, defibrillators, and heart valves used to treat heart disease.
- Neuromodulation: This segment develops and markets devices for chronic pain management and neurological disorders. These include spinal cord stimulators and deep brain stimulation systems.
Leadership and Structure
The CEO is Michael Mahoney. The organizational structure is based on the core business areas, with centralized support functions.
Top Products and Market Share
Key Offerings
- Competitors: Abbott (ABT),Johnson & Johnson (JNJ)
- Watchman FLX: A left atrial appendage closure (LAAC) device to reduce stroke risk in patients with non-valvular atrial fibrillation. It holds a significant market share in LAAC, competing with Abbott's Amulet. Some estimate the company has over 70% of US market share. The product generated revenue in excess of $1B in 2023.
- Competitors: Abbott (ABT),Medtronic (MDT),Johnson & Johnson (JNJ)
- Stents: Boston Scientific offers a range of coronary and peripheral stents used to open blocked arteries. It competes with Abbott, Medtronic, and Johnson & Johnson. The company holds a significant portion of the drug-eluting stent market. Market share information from Q4 2023 suggest that company holds about 20% of the market in the stent/cardiology product segment.
- Competitors: Medtronic (MDT),Abbott (ABT)
- Spinal Cord Stimulators: Devices used for pain management, and an area in which Boston Scientific maintains a strong position in the global market. Competitors include Medtronic and Abbott
Market Dynamics
Industry Overview
The medical device industry is experiencing growth driven by an aging population, technological advancements, and increasing demand for minimally invasive procedures.
Positioning
Boston Scientific is a major player in the medical device industry, known for innovation and a broad product portfolio, enabling it to compete effectively across multiple segments.
Total Addressable Market (TAM)
The global medical device market is estimated to be worth several hundred billion dollars. Boston Scientific is well-positioned to capture a significant portion of this market through its diverse portfolio.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong R&D capabilities
- Global presence and distribution network
- Established brand reputation
- Proven track record of innovation
Weaknesses
- Exposure to product liability risks
- Dependence on regulatory approvals
- Competition from larger medical device companies
- Pricing pressures in some markets
Opportunities
- Expanding into emerging markets
- Developing new and innovative products
- Acquiring complementary businesses
- Increasing adoption of minimally invasive procedures
- Partnerships to develop novel solutions
Threats
- Intense competition
- Changing healthcare regulations
- Economic downturns
- Technological obsolescence
- Increased price sensitivity
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Abbott (ABT)
- Johnson & Johnson (JNJ)
Competitive Landscape
Boston Scientific competes on innovation, product portfolio breadth, and global reach. Its competitive advantage lies in minimally invasive technologies.
Major Acquisitions
Apollo Endosurgery
- Year: 2023
- Acquisition Price (USD millions): 615
- Strategic Rationale: Expanded Boston Scientificu2019s endosurgery portfolio.
Growth Trajectory and Initiatives
Historical Growth: Boston Scientific has experienced consistent growth through organic innovation and acquisitions.
Future Projections: Analysts project continued growth driven by new product launches and market expansion. Expect Revenue to increase 10 to 15% YOY.
Recent Initiatives: Recent initiatives include acquisitions of companies with innovative technologies, such as Apollo Endosurgery.
Summary
Boston Scientific is a strong player in the medical device industry with a diverse portfolio and global reach. Its focus on innovation and strategic acquisitions positions it well for future growth. However, it faces competition and regulatory hurdles that need to be carefully managed. Strong Q1 2024 results have the company optimistic about the rest of the year.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Boston Scientific Investor Relations
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data and projections are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boston Scientific Corp
Exchange NYSE | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1992-05-18 | Chairman, President & CEO Mr. Michael F. Mahoney | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.bostonscientific.com |
Full time employees 53000 | Website https://www.bostonscientific.com | ||
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.